NovaBay Pharmaceuticals (NYSE:NBY) (NYSE:NBY) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary anti-infective and anti-inflammatory products. Founded in 2000 and headquartered in Emeryville, California, NovaBay’s core technology platform is based on Aganocide compounds—synthetic molecules designed to mimic the body’s natural defenses against a range of pathogens. These compounds provide targeted antimicrobial action without contributing to antibiotic resistance, positioning NovaBay as a pioneer in innovative infection control solutions.
NovaBay’s product portfolio includes Avenova, an ophthalmic hygiene solution formulated to treat conditions associated with chronic eye inflammation, such as blepharitis and dry eye. Avenova is distributed through both healthcare practitioners and direct-to-consumer channels, enabling broader access to effective eyelid and ocular surface hygiene care. The company also develops NeutroPhase, a sterile wound-care solution employed in hospitals, outpatient clinics, and military settings to promote wound healing and reduce microbial burden without the harsh side effects of traditional antiseptics.
In addition to its flagship products, NovaBay is advancing a pipeline of next-generation topical anti-infective therapies. The company has entered into strategic collaborations and licensing agreements to expand distribution globally, with partnerships spanning North America, Europe, and Asia. These alliances aim to accelerate regulatory approvals and enhance market penetration across ophthalmology, dermatology, and wound care markets, reflecting NovaBay’s commitment to addressing unmet medical needs through science-driven innovation.
Leadership at NovaBay combines deep industry expertise with scientific prowess. Founder and Chairman Dr. Ronald Najafi, a pioneer in antimicrobial research, guided the original development of Aganocide technology. Current President and Chief Executive Officer Fredric Points, M.D., brings extensive experience in pharmaceutical development and commercialization. Under their stewardship, NovaBay continues to leverage its unique platform to develop safe, effective products that strengthen the body’s natural ability to fight infection and inflammation.
